Topline data from Lysogene’s Phase II/III AAVance study showed its investigational gene therapy, LYS-SAF302, failed to meet its primary and key secondary efficacy endpoints in mucopolysaccharidosis type IIIA.
https://www.pharmalive.com/wp-content/uploads/2022/11/Biospacelabfailure11-21-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-21 11:00:012022-11-21 11:42:16Lysogene becomes latest company to fail with AAVs in CNS disorders